Howard W. Robin Sells 23,774 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 23,774 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total value of $24,011.74. Following the transaction, the chief executive officer now directly owns 1,086,901 shares in the company, valued at $1,097,770.01. This represents a 2.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Nektar Therapeutics Trading Down 2.6 %

Shares of Nektar Therapeutics stock opened at $0.93 on Monday. The stock has a market capitalization of $171.95 million, a price-to-earnings ratio of -1.11 and a beta of 0.58. The business’s 50 day simple moving average is $0.92 and its 200-day simple moving average is $1.12. Nektar Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.93.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NKTR. HC Wainwright reissued a “buy” rating and issued a $6.50 target price on shares of Nektar Therapeutics in a report on Monday, January 13th. B. Riley began coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Finally, Piper Sandler started coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.08.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC grew its holdings in Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 9,958 shares in the last quarter. Harvest Investment Services LLC acquired a new position in Nektar Therapeutics during the fourth quarter worth about $27,000. US Asset Management LLC acquired a new position in shares of Nektar Therapeutics in the 4th quarter worth approximately $31,000. Valence8 US LP bought a new position in shares of Nektar Therapeutics in the third quarter valued at $34,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $41,000. 75.88% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.